NeoGenomics Inc. (NASDAQ:NEO) and DarioHealth Corp. (:), both competing one another are Medical Laboratories & Research companies. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeoGenomics Inc. 22 6.62 N/A 0.07 369.24
DarioHealth Corp. N/A 0.00 N/A -0.78 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for NeoGenomics Inc. and DarioHealth Corp.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
NeoGenomics Inc. 0.00% 2.1% 1.3%
DarioHealth Corp. 0.00% -303.5% -173.1%

Volatility and Risk

NeoGenomics Inc. has a 0.96 beta, while its volatility is 4.00%, thus making it less volatile than Standard & Poor’s 500. DarioHealth Corp.’s 167.00% less volatile than Standard & Poor’s 500 volatility due to the stock’s -0.67 beta.

Liquidity

The current Quick Ratio of NeoGenomics Inc. is 1.5 while its Current Ratio is 1.6. Meanwhile, DarioHealth Corp. has a Current Ratio of 1.4 while its Quick Ratio is 1.1. NeoGenomics Inc. is better positioned to pay off its short-term and long-term debts than DarioHealth Corp.

Analyst Recommendations

Ratings and Recommendations for NeoGenomics Inc. and DarioHealth Corp. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NeoGenomics Inc. 0 0 1 3.00
DarioHealth Corp. 0 0 0 0.00

NeoGenomics Inc.’s upside potential currently stands at 23.63% and an $27 average target price.

Insider & Institutional Ownership

The shares of both NeoGenomics Inc. and DarioHealth Corp. are owned by institutional investors at 77.1% and 16.8% respectively. NeoGenomics Inc.’s share held by insiders are 2.8%. Comparatively, 11.4% are DarioHealth Corp.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NeoGenomics Inc. 3.88% 8.5% 13.35% 47.16% 76.72% 93.26%
DarioHealth Corp. 35.65% 28.42% -30.21% -13.61% -50.41% -21.39%

For the past year NeoGenomics Inc. had bullish trend while DarioHealth Corp. had bearish trend.

Summary

NeoGenomics Inc. beats on 9 of the 9 factors DarioHealth Corp.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. The company is also pursuing patent applications in various jurisdictions covering the specific processes related to blood glucose level measurement, as well as various general methods of rapid tests of body fluids using mobile devices and cloud-based services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. The company was founded in 2011 and is headquartered in Caesarea, Israel.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

(Excerpt) Read more Here | 2019-09-22 22:32:30
Image credit: source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.